Condition: Urothelial Carcinoma · Cancer · Sponsor: Centre Hospitalier Universitaire de Nīmes
Following radical nephrectomy (RNU) for upper tract urothelial carcinoma (UTUC) most patients face a poor prognosis. Indeed, patients who have undergone RNU for UTUC have 5-year recurrence-free and cancer specific survival probabilities of 69% and 73% respectively. The primary objective of this study is to assess the pathological complete response rate to combination therapy with neoadjuvant durvalumab and chemotherapy (Gemcitabine/Cisplatin) before surgery in patients with high-risk, localized, non-metastatic urothelial carcinomas of the upper tract.
This description comes directly from the study's public registry record.
Nadine HOUEDE, Pr. · +33 4 66 68 33 01 · nadine.HOUEDE@chu-nimes.fr
Annissa MEZGARI · +33 4 66 68 30 52 · drc@chu-nimes.fr
Always discuss trial participation with your own doctor first.
| Hôpital Bichat-Claude Bernard | Paris, Paris Cx 20, France | Recruiting |
| Institut Paoli Calmette | Marseille, France | Recruiting |
| Hôpital Saint Louis | Paris, France | Recruiting |
| Hôpital Pitié Salpétrière | Paris, France | Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Recruiting |
| Centre hospitalier Lyon Sud | Pierre-Bénite, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
| Hôpital Foch | Suresnes, France | Recruiting |
| Iuct Oncopole | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04617756